Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors

Preclinical characterization and phase I clinical trial of CT053PTSA targets MET, AXL, and VEGFR2 in patients with advanced solid tumors

BackgroundCT053PTSA is a novel tyrosine kinase inhibitor that targets MET, AXL, VEGFR2, FLT3 and MERTK. Here, we present preclinical data about CT053PTSA, and we conducted the first-in-human (FIH) study to evaluate the use of CT053PTSA in adult patients with pretreated advanced solid tumors.MethodsT...

Full description

Bibliographic Details
Main Authors: Yu-Xiang Ma, Fu-Rong Liu, Yang Zhang, Qun Chen, Zhi-Qiang Chen, Qian-Wen Liu, Yan Huang, Yun-Peng Yang, Wen-Feng Fang, Ning Xi, Ning Kang, Yu-Lei Zhuang, Qi Zhang, Ying-Zhi Jiang, Li Zhang, Hong-Yun Zhao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Immunology
Subjects:
preclinical
phase I
tyrosine kinase inhibitor
MET
AXL
VEGFR2
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1024755/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1024755/full

Similar Items